Which Company Has the Best Dividend -- Johnson & Johnson, Pfizer, or Merck?

These three questions will help investors determine which big pharma company -- Johnson & Johnson, Pfizer, or Merck -- offers the best long-term dividend.

Feb 27, 2014 at 2:30PM

Many investors often associate the health care sector with volatile biotech stocks that can soar or plunge by double digits in a single day. However, investors shouldn't overlook the big names in the pharmaceutical field such as Johnson & Johnson (NYSE:JNJ), Pfizer (NYSE:PFE), and Merck (NYSE:MRK), which offer stable, long-term returns and generous dividends instead of back-breaking roller-coaster thrills.

Let's discuss which of these three big pharma companies offers the best dividend and stability for more passive income investors.

Which company offers the biggest yield?
Let's first compare the trailing, forward, and five-year average annual dividend yields of these three companies.

 

Trailing Annual Dividend Yield

Forward Annual Dividend Yield

5-Year Average
Dividend Yield

Johnson & Johnson

2.9%

2.8%

3.3%

Pfizer

3.1%

3.3%

3.6%

Merck

3.1%

3.5%

4.1%

Source: Yahoo Finance, February 25.

J&J clearly trails Pfizer and Merck in this department. In addition, J&J's stock price has trailed both companies over the past five years:

JNJ Chart

Source: YCharts.

Therefore, in terms of yield and price appreciation, J&J initially looks like a weaker investment than Pfizer and Merck. However, investors should remember that J&J is the largest of these three giants -- with a market cap of $257 billion, compared to Pfizer's $207 billion and Merck's $164 billion -- and, as such, is expected to grow at a slower rate.

Which company is the most generous?
Yet a company's dividend yield is only part of the big picture. The cash payout ratio, or the percentage of a company's free cash flow, or FCF, paid back to the investors, also reveals how generous a company is toward its shareholders. Because FCF data are not yet available for all three companies, I have included information from third quarter 2012 to third quarter 2013.

MRK Cash Dividend Payout Ratio (TTM) Chart

MRK Cash Dividend Payout Ratio (TTM) data by YCharts

Pfizer's cash dividend payout ratio is the lowest among these three..

Which company has the best history of boosting its dividend?
Meanwhile, a company's history of boosting its dividend speaks volumes about its commitment toward long-term shareholders. Let's take a look at the annual dividends of these three companies over the past five fiscal years.

Fiscal Year

Johnson
& Johnson

Pfizer

Merck

2009

$1.93

$0.80

$1.52

2010

$2.11

$0.72

$1.52

2011

$2.25

$0.80

$1.52

2012

$2.40

$0.88

$1.68

2013

$2.59

$0.96

$1.72

Percent change between 2009 and 2013

34%

20%

13%

Source: Capital IQ, February 25, author's calculations.

J&J has been able to continuously increase its dividend by more than Pfizer and Merck -- mainly due to billion-dollar patent cliffs at the latter two.

Pfizer's blockbuster cholesterol drug Lipitor, which generated peak sales of $13 billion, lost patent protection in 2011. To stabilize its bottom line, Pfizer cut jobs, sold off several non-core businesses, and reduced its dividend. Merck also sustained a similar blow when its blockbuster asthma treatment Singulair, which generated peak sales of $5 billion, went off patent in 2012.

By comparison, the only significant patent expiration for J&J in the next five years is Remicade, its best-selling rheumatoid arthritis treatment, which will go off patent in Europe in 2015 and in the U.S. in 2018. However, Remicade isn't Lipitor or Singulair -- the drug only accounts for 9% of J&J's top line. Therefore, J&J is unlikely to stop its tradition of raising its dividend every year.

The Foolish bottom line
With three core businesses -- consumer health care, branded pharmaceuticals, and medical devices -- J&J is the most diversified and well-balanced choice of the three. By comparison, Merck and Pfizer are much more focused on branded pharmaceuticals, which can experience more volatility due to patent expirations and generic competition.

However, both Pfizer and Merck have controlled their bottom lines and dividends with admirable discipline in times of adversity. As a result, their investors have been handsomely rewarded for staying with them for the long term. Therefore, even though J&J is the best "set it and forget it" option for novice investors, Pfizer and Merck are also solid long-term income investments that can stomach a few bumps along the way.

Want to take a break from the volatile biotech sector with a solid long-term investment?
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Leo Sun has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers